Two major medical trusts in the UK are preparing to implement the innovative PinPoint AI blood test for diagnosing uterine cancer in women with suspicious symptoms. This represents a significant breakthrough that could fundamentally change the approach to screening for one of the most common gynecological cancers.
99% Accuracy: How It Works
In a clinical study involving 3,313 women, the machine learning algorithm demonstrated an impressive 99% accuracy in detecting and, equally importantly, ruling out uterine cancer. Every year in England, about 90,000 patients are referred for examination due to heavy postmenopausal bleeding. Of these, approximately 10,000 receive a confirmed diagnosis, and 2,700 women die from the disease annually.
The standard procedure includes transvaginal ultrasound and, if suspicions arise, a painful biopsy with hysteroscopy. However, 20% of those referred do not have cancer confirmed—these women undergo invasive procedures unnecessarily. PinPoint analyzes 30 biomarkers in a blood sample and divides patients into low, elevated, and high-risk groups. According to developers' estimates, this will allow the disease to be ruled out at the initial consultation stage, sparing about 18,000 women per year from unnecessary interventions.
Implementation and Prospects
The technology, created by Leeds-based company PinPoint Data Science, has already undergone large-scale trials involving 16,481 patients from 170 clinics in Yorkshire. The company's Chief Medical Officer, Sean Duffy, emphasizes that 99% accuracy is an outstanding result, but the key advantage is reliably ruling out cancer in low-risk women. Mid Yorkshire NHS Teaching Trust plans to use the test for six types of gynecological cancer and upper gastrointestinal cancer, while Leeds Teaching Hospitals NHS Trust will apply it to all gynecological cancers.
Doctors note that currently, ruling out cancer requires up to six visits, and the new technology will speed up the process, allowing genuinely ill patients to be referred for treatment more quickly. Consultant gynecologist Tracy Jackson from Leeds Trust emphasizes: "Women with cancer will see a doctor faster, receive a diagnosis, and begin treatment." Cancer Research UK calls the results "promising" but calls for additional research to assess long-term benefits.
My comment as an analyst: This is not just another medical startup, but an example of how AI solves a fundamental problem—the overload of the healthcare system. If the test scales, we will see a reduction in mortality not only from uterine cancer but also from other cancers due to early diagnosis. However, the key challenge is integrating such algorithms into routine clinical practice and standardizing data.